Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue (1) | $20,156 | $39,134 | $39,630 | $77,364 |
| Costs and operating expenses: | ||||
| Cost of other revenue | 1,719 | 5,380 | 4,817 | 9,470 |
| Research and development | 46,210 | 53,370 | 96,130 | 124,293 |
| General and administrative | 30,775 | 34,981 | 68,605 | 74,704 |
| Restructuring charges | — | 3,566 | — | 8,032 |
| Total operating expenses | 78,704 | 97,297 | 169,552 | 216,499 |
| Loss from operations | (58,548) | (58,163) | (129,922) | (139,135) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's R&D?
- Ginkgo Bioworks (DNA) reported R&D of $46.21M in Q2 2026.
- How has Ginkgo Bioworks's R&D changed year-over-year?
- Ginkgo Bioworks's R&D decreased by 13.4% year-over-year, from $53.37M to $46.21M.
- What is the long-term trend for Ginkgo Bioworks's R&D?
- Over 4 years (2021 to 2025), Ginkgo Bioworks's R&D has grown at a -32.1% compound annual growth rate (CAGR), from $1.15B to $243.77M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Ginkgo Bioworks's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude